References:

[1] Paul Bradley,Michael Shiekh,Vishaal Mehra,Keith Vr-bicky,Stacey Layle,Marilyn C. Olson,Alejandra Maciel,Ali Cullors, Jorge A. Garces, Andrew A. Lukowiak. Im-proved efficacy with targeted pharmacogenetic - guidedtreatment of patients with depression and anxiety: A ran-domized clinical trial demonstrating clinical utility [ J ].Journal of Psychiatric Research,2018,96.
[2]Barbw D H. 心理障碍临床手册[ M]. 刘兴华,译. 3 版,北京:中国轻工业出社,2004:287 - 300.
[3]陶建青,龚冀荣,陆锦滢,等. 我国综合医院患者抑郁焦虑障碍患病率的 Meta 分析[ J]. 四川精神卫生,2018,31(1):73 - 78.
[4]杜巧琳,王小云. 抑郁症病因研究[ J]. 现代中西医结合杂志,2003,12(1):106 - 108.
[5]瞿伟,谷珊珊. 抑郁症治疗研究新进展[ J]. 第三军医大学学报,2014,36(11):1113 - 1117.
[6]Hayley S,Poulter M O,Merall Z,et al. The Pathogenesis ofClinical Depression:Stressor and Cytokine Induced Alterations of Neuroplasticity. Neuroscience, 2005, 135: 659- 678.
[7]董海影,张晓杰. 柴胡疏肝散对抑郁模型大鼠海马乙酰胆碱代谢的影响. 中华中医药杂志,2011,26 (1):163- 167.
[8]王联生,黄世敬. 柴胡疏肝散抗抑郁研究进展[ J]. 世界中医药,2015,10(9):1453 - 1456.